
Dermatology Times 2024 In Review: Skin Cancer
As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in skin cancer this year.
The promising results were presented in a poster at the 2024 Winter Clinical Hawaii Dermatology Conference in Honolulu, Hawaii.
A study found that combining dermoscopy with RCM not only improved diagnostic accuracy but also improved diagnostic certainty.
SXRT may present a cost-effective and surgery-free therapeutic option for patients with non-aggressive BCC and SCC.
The Skin Cancer Foundation’s initiative, Destination Healthy Skin, travels to various cities throughout the country in an RV, wherein volunteer dermatologists provide on-the-street, free-of-cost skin screenings.
The test may help patients with melanoma safely avoid a sentinel lymph node biopsy.
The 2-GEP test is made of 2 biomarkers, LINC00518 and PRAME.
In most kidney transplant recipients with advanced skin cancer, 2 checkpoint inhibitors are needed to boost the immune system, according to study
Rebecca Hartman, MD, MPH, FAAD, and Christine Kannler, MD, FAAD, took a deep dive into considerations and pearls to treat patients who have been exposed to extreme heat and chemicals in the line of duty.
Vulnerable populations such as the prison population should have access to Mohs surgery to prevent the increased risk of morbidity and mortality from skin cancer.
Diagnostic accuracy of lesions was enhanced with combined dermoscopy and reflectance confocal microscopy, according to one study.
A review found that Mohs micrographic surgery and conventional excision yielded comparable patient reported outcomes.
Study findings suggest OCT's effectiveness in accurately diagnosing and mapping BCC, with a high predictive capability for Mohs surgery requirements.
Researchers found that the diameter of cutaneous melanoma demonstrated a weak positive correlation with tumor thickness.
Muscle spasms are the most common adverse event experienced by patients treated with hedgehog inhibitors for basal cell carcinomas.
While MMS is recognized as the gold standard for skin cancer treatment, numerous challenges still hinder widespread adoption and practice.
Phase 3 trials have been initiated in patients with high-risk melanoma.
To address the increased rates of skin cancer while keeping unique patient needs top of mind, there is a pressing need to increase options for treatment.
Peter Prieto, MD, MPH, shares details of the IOV-COM-202 trial.
A recent study offers a comprehensive analysis of practice patterns and patient characteristics in different clinical settings.
The guidelines for BCC and SCC treatment with IGSRT detail diagnosis, staging, contraindications, protocols, and emphasize the essential role of a multidisciplinary team.
Margins < 1 mm also do not increase the risk of cutaneous squamous cell carcinoma recurrence risk if the galea aponeurotica is not involved.
To improve overall outcomes for patients with large basal cell carcinomas, it has been beneficial to employ the use of vismodegib as a neoadjuvant and/or adjuvant treatment.
A comprehensive analysis of 71 studies revealed the highest lesion clearance and recurrence rates among individuals who had undergone surgery.
Researchers tailored screening and surveillance schedules to individual risk of patients.
The PD-1/IL-2α bispecific antibody fusion protein is intended for patients with unresectable locally advanced or metastatic melanoma.
Swiss researchers found significant gender differences in melanoma care, including variations in information preferences and treatment decision-making.
Data was published in the Journal of the American Board of Family Medicine.
Nicole A. Negbenebor, MD, FAAD, discusses the benefits of intralesional 5-fluorouracil injection for older patients with squamous cell carcinoma who may elect to delay therapy or are not ideal candidates for surgery.
The study underscores the importance of addressing work-related concerns for patients with melanoma, advocating for effective communication about rehabilitation options.
Motivators like health benefits, altruism, and trust in clinicians enhance participant retention and adherence in melanoma research, according to MEL-SELF findings.
Pediatric melanoma, though rare, is the deadliest skin cancer in children, with 300-500 US cases annually.
Certain factors may contribute to higher occurrences of non-melanoma skin cancer in these patients, according to a novel systemic review.
Researchers recommend limiting routine lipase tests to symptomatic patients or those with radiographic signs of pancreatic injury.
Despite the risks of sun exposure, a study found only a fraction of coaches receive adequate UV-related guidance from their associations or clubs.
Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















